SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001636050-20-000049
Filing Date
2020-09-28
Accepted
2020-09-28 16:56:54
Documents
1
Period of Report
2020-09-24
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K axovant-2020annualmeet.htm 8-K 53340
  Complete submission text file 0001636050-20-000049.txt   54716
Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Filer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37418 | Film No.: 201205148
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences